DK1902029T4 - Krystallinske former af 4-[(2,4-dichlor-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-3-quinolincarbonitril og fremgangsmåder til fremstilling deraf - Google Patents

Krystallinske former af 4-[(2,4-dichlor-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-3-quinolincarbonitril og fremgangsmåder til fremstilling deraf Download PDF

Info

Publication number
DK1902029T4
DK1902029T4 DK06774184.3T DK06774184T DK1902029T4 DK 1902029 T4 DK1902029 T4 DK 1902029T4 DK 06774184 T DK06774184 T DK 06774184T DK 1902029 T4 DK1902029 T4 DK 1902029T4
Authority
DK
Denmark
Prior art keywords
quinolincarbonitrile
crystallic
piperazinyl
methoxyphenyl
propoxy
Prior art date
Application number
DK06774184.3T
Other languages
English (en)
Other versions
DK1902029T3 (da
Inventor
Marc Sadler Tesconi
Gregg Feigelson
Henry Strong
Hong Wen
Original Assignee
Wyeth Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37103295&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1902029(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Llc filed Critical Wyeth Llc
Application granted granted Critical
Publication of DK1902029T3 publication Critical patent/DK1902029T3/da
Publication of DK1902029T4 publication Critical patent/DK1902029T4/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Medicinal Preparation (AREA)
DK06774184.3T 2005-07-01 2006-06-28 Krystallinske former af 4-[(2,4-dichlor-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-3-quinolincarbonitril og fremgangsmåder til fremstilling deraf DK1902029T4 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US69638105P 2005-07-01 2005-07-01
PCT/US2006/025160 WO2007005462A1 (en) 2005-07-01 2006-06-28 Crystalline forms of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-3-quinolinecarb-onitrile and methods of preparing the same

Publications (2)

Publication Number Publication Date
DK1902029T3 DK1902029T3 (da) 2014-02-17
DK1902029T4 true DK1902029T4 (da) 2022-02-28

Family

ID=37103295

Family Applications (1)

Application Number Title Priority Date Filing Date
DK06774184.3T DK1902029T4 (da) 2005-07-01 2006-06-28 Krystallinske former af 4-[(2,4-dichlor-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-3-quinolincarbonitril og fremgangsmåder til fremstilling deraf

Country Status (25)

Country Link
US (2) US7767678B2 (da)
EP (1) EP1902029B2 (da)
JP (1) JP2009500332A (da)
KR (1) KR20080028386A (da)
CN (1) CN101248047A (da)
AR (1) AR054505A1 (da)
AU (1) AU2006266045A1 (da)
BR (1) BRPI0613574A2 (da)
CA (1) CA2613053C (da)
CR (1) CR9596A (da)
DK (1) DK1902029T4 (da)
EC (1) ECSP078063A (da)
ES (1) ES2449197T5 (da)
GT (1) GT200600282A (da)
HK (1) HK1114614A1 (da)
IL (1) IL188483A0 (da)
MX (1) MX2008000384A (da)
NO (1) NO20080051L (da)
PA (1) PA8685101A1 (da)
PE (1) PE20070190A1 (da)
PL (1) PL1902029T5 (da)
PT (1) PT1902029E (da)
RU (1) RU2007148072A (da)
TW (1) TW200740797A (da)
WO (1) WO2007005462A1 (da)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2448563A2 (en) * 2009-07-02 2012-05-09 Wyeth LLC 3-cyanoquinoline tablet formulations and uses thereof
WO2013187967A1 (en) 2012-06-15 2013-12-19 Institute For Cancer Research D/B/A The Research Institute Of Fox Case Cancer Center ("Fox Chase Cancer Center") Sensitization of cancer cells to dna damage by inhibiting kinases essential for dna damage checkpoint control
CN104447541A (zh) * 2013-09-16 2015-03-25 天津市汉康医药生物技术有限公司 博舒替尼化合物
IN2014CH00840A (da) * 2014-02-20 2015-09-18 Apotex Inc
WO2015149727A1 (en) 2014-04-02 2015-10-08 Zentiva, K.S. Novel solid phases of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-1 -piperazinyl)propoxy]-3-quinolinecarbonitrile
WO2016034150A1 (zh) * 2014-09-04 2016-03-10 正大天晴药业集团股份有限公司 博舒替尼及其结晶的制备方法
CN105384686B (zh) * 2014-09-04 2019-07-26 连云港润众制药有限公司 一种博舒替尼结晶方法
WO2017029584A1 (en) * 2015-08-19 2017-02-23 Sun Pharmaceutical Industries Limited Amorphous form of bosutinib
WO2017134679A1 (en) * 2016-02-03 2017-08-10 Msn Laboratories Private Limited Novel crystalline polymorphs of 4-[(2.4-dichioro-5-methoxvphenvl)aniinol- 6-methoxv-7-13-(4-methyl-l-piperazinvl)propoxvl-3-quinolinecarbonitrile and process for preparation thereof
WO2017145089A1 (en) * 2016-02-23 2017-08-31 Sun Pharmaceutical Industries Limited Crystalline form x of bosutinib
CN105646345A (zh) * 2016-03-16 2016-06-08 浙江海正药业股份有限公司 博舒替尼的新晶型及其制备方法
CN106187886B (zh) * 2016-07-06 2019-04-16 山东创新药物研发有限公司 一种制备高纯度伯舒替尼一水合物的方法
JOP20190144A1 (ar) 2016-12-16 2019-06-16 Janssen Pharmaceutica Nv إيميدازو بيرولو بيريدين كمثبطات لعائلة jak الخاصة بإنزيمات الكيناز
CN110317168A (zh) * 2018-03-30 2019-10-11 正大天晴药业集团股份有限公司 一种博舒替尼的纯化方法
TW202016110A (zh) 2018-06-15 2020-05-01 比利時商健生藥品公司 Ｊａｋ激酶家族之小分子抑制劑
WO2020209843A1 (en) 2019-04-09 2020-10-15 Massachusetts Institute Of Technology A micro physiological model for neuronal and muscular diseases and disorders
CN112321505B (zh) * 2019-10-25 2022-08-23 杭州中美华东制药有限公司 一种伯舒替尼晶型及其制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6002008A (en) * 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
US6432979B1 (en) * 1999-08-12 2002-08-13 American Cyanamid Company Method of treating or inhibiting colonic polyps and colorectal cancer
UA77200C2 (en) * 2001-08-07 2006-11-15 Wyeth Corp Antineoplastic combination of cci-779 and bkb-569
TWI275390B (en) * 2002-04-30 2007-03-11 Wyeth Corp Process for the preparation of 7-substituted-3- quinolinecarbonitriles
TW200423938A (en) * 2003-02-21 2004-11-16 Wyeth Corp 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-alkoxy-3-quinolinecarbonitriles for the treatment of ischemic injury
RU2345069C2 (ru) * 2003-08-19 2009-01-27 Уайт Холдингз Корпорейшн Способ получения 4-амино-3-хинолинкарбонитрилов
WO2005065074A2 (en) * 2003-09-09 2005-07-21 Temple University Of The Commonwealth System Of Higher Education Protection of tissues and cells from cytotoxic effects of ionizing radiation by abl inhibitors
AU2003291245A1 (en) * 2003-11-06 2004-06-06 Wyeth 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (cml)
US7910211B2 (en) * 2005-06-20 2011-03-22 E.I. Du Pont De Nemours And Company Process for the production of multi-layer coatings
MX2007016542A (es) * 2005-06-24 2008-03-04 Wyeth Corp 4-anilino-3-quinolinocarbonitrilos para el tratamiento de cancer.
US8520232B2 (en) * 2006-03-31 2013-08-27 Konica Minolta Laboratory U.S.A., Inc. Print job analyzing method and apparatus with print device recommendation functions

Also Published As

Publication number Publication date
PL1902029T5 (pl) 2022-08-29
BRPI0613574A2 (pt) 2016-11-16
WO2007005462A1 (en) 2007-01-11
US20100324066A1 (en) 2010-12-23
HK1114614A1 (en) 2008-11-07
GT200600282A (es) 2007-02-14
PL1902029T3 (pl) 2014-08-29
DK1902029T3 (da) 2014-02-17
KR20080028386A (ko) 2008-03-31
AR054505A1 (es) 2007-06-27
ES2449197T5 (es) 2022-04-28
NO20080051L (no) 2008-01-29
CR9596A (es) 2008-03-06
US20070015767A1 (en) 2007-01-18
CA2613053A1 (en) 2007-01-11
EP1902029B1 (en) 2014-01-08
US7767678B2 (en) 2010-08-03
IL188483A0 (en) 2008-04-13
CA2613053C (en) 2015-11-24
EP1902029B2 (en) 2022-02-16
TW200740797A (en) 2007-11-01
CN101248047A (zh) 2008-08-20
PA8685101A1 (es) 2007-01-17
JP2009500332A (ja) 2009-01-08
AU2006266045A1 (en) 2007-01-11
RU2007148072A (ru) 2009-08-10
ECSP078063A (es) 2008-01-23
MX2008000384A (es) 2008-03-07
US8445496B2 (en) 2013-05-21
ES2449197T3 (es) 2014-03-18
PT1902029E (pt) 2014-03-05
PE20070190A1 (es) 2007-03-20
EP1902029A1 (en) 2008-03-26

Similar Documents

Publication Publication Date Title
DK1902029T4 (da) Krystallinske former af 4-[(2,4-dichlor-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-3-quinolincarbonitril og fremgangsmåder til fremstilling deraf
NO2017035I1 (no) Nintedanib, 3-Z-{1-(4-(N-((4-metyl-piperazin-1-y-metylkarbonyl)-N-metyl-amino)-anilino)-1-fenylmetylenj- 6-metoksykarbonyl-2-indolinon
EE200300385A (et) 3-(4-amidopürrool-2-üülmetülideen)-2-indolinooni derivaadid kui proteiini kinaasi inhibiitorid
DK3238543T3 (da) Eukaryote mikroorganismer til fremstilling af lipider og antioxidanter
DK1667986T3 (da) Acetonesolvat af dimethoxydocetaxel og fremgangsmåde til fremstilling heraf
DK1976868T3 (da) Edderkoppesilke-proteiner og fremgangsmåde til fremstilling af edderkoppesilke-proteiner
DK1874557T3 (da) Identitetsdokument og fremgangsmåde til fremstilling deraf
DK2057153T3 (da) (3-aryl-piperazin-1-yl)-derivater af 6,7 dialkoxyquinazolin, 6,7- dialkoxyphtalazin og 6,7-dialkoxyisoquinolin
DK1937824T3 (da) Sammensætninger af tRNA og anvendelser deraf
DK3889142T3 (da) 1,2,4-oxadiazolbenzoesyreforbindelser og deres anvendelse til nonsense-suppression og behandling af sygdom
DK1916995T4 (da) Ph-styret, pulserende indgivelsessystem, fremgangsmåder til fremstilling og anvendelse deraf
DK1765327T3 (da) Forbindelser, sammensætninger og fremgangsmåder
DK1928457T3 (da) Quinoliner og deres terapeutiske anvendelse
DK1455785T3 (da) Substituerede 2-thio-3,5-dicyano-4-phenyl-6-aminopyridiner og deres anvendelse
DK1844337T3 (da) Bindingsforbindelser, immunogene forbindelser og peptidmimetika
DK1701968T3 (da) Immunogene peptid-bærer-konjugater og fremgangsmåder til deres fremstilling
DK3309233T4 (da) Sammensætninger omfattende hfc-1234yf og hfc-152a
IS8040A (is) Arómatískt oxýfenýl og arómatískar súlfanýlfenýl afleiður
DK2402005T3 (da) Formuleringer med langvarig frigivelse af nalbuphin
DK1651644T3 (da) Substituerede derivater af thiazol-benzoisothiazoldioxid, fremgangsmåde deraf og deres anvendelse
DK1488180T3 (da) Fremgangsmåde til tørring af vandige fluider med højt lactoseindhold
DK1976548T3 (da) VIP-fragmenter og sammensætninger deraf
DK1896439T3 (da) Krystallinsk base af escitalopram og orodispergerbare tabletter, der omfatter escitaloprambase
DK1812002T3 (da) Behandling af mastitis
DK1783105T3 (da) Mørtelsammensætning, fremgangsmåde til fremstilling og anvendelse deraf